Ascendis (Danish) makes long-acting hormone therapies.
Ascendis Pharma A/S (ASND) is expected to report earnings on Wednesday, November 11, 2026, after the close. Consensus EPS estimate is $1.21.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-13 | FY2026 Q2 | $1.71 | $3.29 | +92.4% | $387.48M |
| 2026-05-07 | FY2026 Q1 | $0.19 | $0.32 | +70.6% | $284.92M |
| 2025-11-12 | FY2025 Q3 | $-0.41 | $-1.17 | -185.4% | $250.22M |
| 2025-08-07 | FY2025 Q2 | $-1.42 | $-0.93 | +34.5% | $186.09M |
| 2025-05-01 | FY2025 Q1 | $-1.56 | $-1.66 | -6.4% | $110.67M |
| 2025-02-12 | FY2024 Q4 | $-1.20 | $-0.68 | +43.3% | $180.09M |
| 2024-11-14 | FY2024 Q3 | $-1.83 | $-1.81 | +1.1% | $63.43M |
| 2024-09-03 | FY2024 Q2 | $-1.54 | $-2.05 | -33.1% | $38.71M |
ASND has beaten consensus EPS in 5 of its last 8 reported quarters.
ASND reported Aug 13. The highlights: EPS of $3.29 — a big beat vs the $1.71 estimate (+92%); revenue of $387M — a beat vs the $377M consensus (+3%). Focus now shifts to Yorvipath launch trajectory.
See ASND on the live calendar →